


Synthetic mRNA-based approaches for tissue regeneration– Application potential for the treatment of osteoarthritis

Prof. Dr. rer. nat. Meltem Avci-Adali

University Hospital Tübingen

Dept. of Thoracic and Cardiovascular Surgery



Reprogramming of somatic cells into induced pluripotent stem cells (iPSCs)

Cell

Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors


Kazutoshi Takahashi¹ and Shinya Yamanaka^{1,2,*}

¹Department of Stem Cell Biology, Institute for Frontier Medical Sciences, Kyoto University, Kyoto 606-8507, Japan

²CREST, Japan Science and Technology Agency, Kawaguchi 332-0012, Japan

*Contact: yamanaka@frontier.kyoto-u.ac.jp


DOI 10.1016/j.cell.2006.07.024



Jointly with Sir John B. Gurdon
Nobel Prize 2012
in Physiology or Medicine



Reprogramming of somatic cells into induced pluripotent stem cells (iPSCs)



Modifiziert aus <http://www.lebao.de> / <http://www.eurostemcell.org/de>

Disadvantages of these methods

→ **Use of retroviral vectors**

→ Genome integration → Induction of mutagenesis

Problem:


→ cannot be clinically applied

How can mutations be prevented?




Use of non-mutagenic molecules is required:
→ Synthetic mRNAs

Modified synthetic messenger RNA (mRNA)





Exogenous delivery of modified synthetic messenger RNA (mRNA)



Avci-Adali M., et al. (2014) *J Biol Eng.* 8(1):8


Transfection of cells with modified synthetic mRNA



Avci-Adali M., et al. (2014) *J Biol Eng.* 8(1):8

Generation of iPSCs

→ Treatment of human fibroblasts with Yamanaka factors (Oct4, Klf4, cMyc, Lin28, and Sox2) encoding mRNAs for the generation of iPSCs




Disadvantages of synthetic mRNA-based method

- Daily transfection / treatment
- Expensive and time-consuming
- Low efficiency

Self-replicating mRNA (srRNA)


VEE (Venezuelan equine encephalitis)



Steinle H, ..., & **Avci-Adali M.** *Stem Cells Int.* (2019) 2019:7641767
Umrath F, ..., & **Avci-Adali M.** *Int J Mol Sci.* (2019), 20(7):1648


~ 15 kb

Reprogramming of urine-derived renal epithelial cells into iPSCs



Reprogramming of urine-derived renal epithelial cells into iPSCs


Human renal epithelial cells





srRNA



iPSCs




Reprogramming of urine-derived renal epithelial cells into iPSCs



Steinle, H.,... Avci-Adali, M. 2019. *Molecular Therapy-Nucleic Acids*, 17, 907-921.

Reprogramming of urine-derived renal epithelial cells into iPSCs




Steinle, H.,... Avci-Adali, M. 2019. *Molecular Therapy-Nucleic Acids*, 17, 907-921.

Self-replicating mRNA (srRNA)

- Only one single transfection is required
- Higher reprogramming efficiency
- No integration into host genome

Differentiation of iPSCs into cardiomyocytes



Generation of beating cardiomyocytes







Molecular Therapy
Nucleic Acids
 Original Article



Reprogramming of Urine-Derived Renal Epithelial Cells into iPSCs Using srRNA and Consecutive Differentiation into Beating Cardiomyocytes

Heidrun Steinle,^{1,4} Marbod Weber,^{1,4} Andreas Behring,¹ Ulrike Mau-Holzmann,² Christiane von Ohle,³ Aron-Frederik Popov,¹ Christian Schlensak,¹ Hans Peter Wendel,¹ and Meltem Avcı-Adalı¹

¹Department of Thoracic and Cardiovascular Surgery, University Hospital Tübingen, Calwerstraße 7/1, 72076 Tübingen, Germany; ²Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen, Calwerstraße 7, 72076 Tübingen, Germany; ³Department of Conservative Dentistry and Periodontology, Centre of Dentistry, Oral Medicine and Maxillofacial Surgery, University Hospital Tübingen, Osianderstraße 2-8, 72076 Tübingen, Germany





Generation of autologous iPSCs for bone regeneration

Dept. of Oral and Maxillofacial Surgery

DFG Deutsche Forschungsgemeinschaft

Stem Cell-powered Implants to Revolutionize Maxillofacial Surgery




Contains Servier Medical Art templates, licensed under a Creative Commons Attribution 3.0 Generic License <http://smart.servier.com/>

iPSC generation from jaw periosteum cells (JPCs) for bone tissue engineering

Umraht F,..., & Avci-Adali M. *Int J Mol Sci.* (2019), 20(7):1648

mRNA delivery of a cartilage-anabolic transcription factor as a disease-modifying strategy for osteoarthritis treatment

→ Polyplex nanomicelles containing cartilage-anabolic transcription factor RUNX1 mRNA




Aini H, et al. Scientific reports. 2016, 6(1):18743.

→ Delivery of RUNX1 mRNA successfully suppressed the progression of OA in mouse knee joints compared with non-treated group

→ Expression of cartilage-anabolic and proliferation markers was increased in articular chondrocytes of the RUNX1 mRNA injected knees


Cartilage-targeting mRNA-lipid nanoparticles rescue perifocal apoptotic chondrocytes for integrative cartilage repair



Yu X, et al. Chemical Engineering Journal. 2023;465:142841.

- IGF-1 mRNA was encapsulated into ionizable lipid nanoparticles (LNPs)
- CAQK peptide modification of LNPs led to improved penetration of cartilage and prolonged retention in the joint cavity
- IGF-1 mRNA loaded LNPs showed robust reversal of chondrocyte apoptosis
- In a full-thickness chondral defect model, IGF-1 mRNA loaded LNPs maintained interfacial cellularity and prevented matrix degradation.

Anti-Inflammatory Therapy for Temporomandibular Joint Osteoarthritis Using mRNA Medicine Encoding Interleukin-1 Receptor Antagonist




Deng J, et al. *Pharmaceutics*. 2022;14(9):1785.

The temporomandibular joint (TMJ) OA causes long-lasting joint pain with chronic inflammation.

→ To develop an anti-inflammatory therapy, interleukin-1 receptor antagonist (IL-1Ra) encoding mRNA loaded polyplex nanomicelles were injected into the rat model of the TMJs

→ A single administration of 2.5 μg of IL-1Ra mRNA provided sustained pain relief and an inhibitory effect on OA progression for 4 weeks.

Highly efficient healing of critical sized articular cartilage defect in situ using a chemically nucleoside-modified mRNA-enhanced cell therapy



TGF-β3 plays a key role in cartilage regeneration and it can induce chondrogenic differentiation of MSCs and promote cartilage-like matrix deposition.

Zhong G, et al. bioRxiv. 2022, 2022-05.



→ Single injection of collagen I containing BMSCs without or with 20 μg modified TGF-β3 mRNA into the critical-sized cartilage defects of rats

Highly efficient healing of critical sized articular cartilage defect in situ using a chemically nucleoside-modified mRNA-enhanced cell therapy



Zhong G, et al. bioRxiv. 2022, 2022-05.

Sham group: without cartilage defect
 Control group: cartilage defect creation and injection of PBS
 CB group: injection of Collagen I and BMSCs mixture
 CmR group: injection of Collagen I and TGFβ3 mRNA
 CBmR group: injection of Collagen I, BMSCs, and TGFβ3 mRNA




- Group injected with collagen I, BMSCs, and TGFβ3 mRNA showed a smooth joint surface and improved cartilage regeneration after 4 and 6 weeks
- Compared to the group without TGF-β3 mRNA reduced subchondral bone abnormalities increased cartilage thickness, filling of the defect, and an increase in type II collagen were detected.
- μCT analyses showed that TGF-β3 mRNA not only promoted cartilage regeneration but also inhibited the pathological changes of subchondral bone

Conclusion

Synthetic mRNA technology offers several potential application possibilities for the treatment of osteoarthritis:

- Disease-Modifying Osteoarthritis Drugs
 - Synthetic mRNAs encoding proteins that promote the synthesis of ECM components or inhibit cartilage-degrading enzymes to prevent the progression of OA
- Pain Management
 - Synthetic mRNAs encoding proteins for pain relief
- Growth Factors
 - Stimulate the production of new cartilage tissue and enhance the healing process
- Prevention of inflammation
 - Synthetic mRNAs encoding anti-inflammatory proteins to reduce inflammation and slow down the progression of the disease

Thank you for your attention!



EBERHARD KARLS
UNIVERSITÄT
TÜBINGEN





Universitätsklinikum
Tübingen

Combination of synthetic mRNA with implants

Article


Exogenous Delivery of Link N mRNA into Chondrocytes and MSCs—The Potential Role in Increasing Anabolic Response

Gauri Tendulkar ^{1,*}, Sabrina Ehnert ¹, Vrinda Sreekumar ¹, Tao Chen ¹, Hans-Peter Kaps ¹, Sonia Golombek ², Hans-Peter Wendel ², Andreas K. Nüssler ¹ and Meltem Avcı-Adalı ²








BG Klinik Tübingen

Siegfried Weller Institute for
Trauma Research



Footprint-free generation of autologous hepatocytes



Possible application in liver tissue engineering and drug testing

DITF


DEUTSCHE INSTITUTE FÜR
TEXTIL+FASERFORSCHUNG

Innovative aspects of the strategy

- ✓ **Self-replicating mRNA is degradable and not genome-integrating**
 - No induction of mutagenesis
 - Generation of clinically applicable cells
- ✓ **Non-invasive collection of patient cells from urine**
 - Destruction of healthy tissue not necessary
- ✓ **Generation of desired cells from patient's own somatic cells**
 - autologous cells
 - no rejection reactions
 - personalized treatment
- ✓ **Regeneration of tissues**

Acute myocardial infarction - loss of cardiomyocytes

Heart attack #1 cause of death




<http://www.mdguidelines.com/myocardial-infarction-acute>

- Death of cardiomyocytes
- Very low proliferation ability of adult cardiomyocytes
- Scar tissue replacement




Impaired heart function

Therapy approaches for the regeneration of the heart muscle



Modifiziert nach Ptaszek L.M., et al., Lancet (2012) 379 (9819): 933-42

Modified synthetic messenger RNA (mRNA)




Beck JD, et al. mRNA therapeutics in cancer immunotherapy. *Molecular cancer*. 2021, 20(1):1-24.

Implantable cells


| Cells | Advantages | Disadvantages |
|--------------------------------|---|---|
| Skeletal myoblasts | Easy to isolate High proliferation rate Hypoxia-resistant Autologous | Incidence of cardiac arrhythmias |
| Stem cells from bone marrow | Easy to isolate Multipotent Low immune responses Autologous | Limited availability Bone and cartilage generation in myocardium |
| Stem cells from adipose tissue | Easy to isolate High Availability Multipotent Low immune responses | Low survival |
| Kardiale Stammzellen | Multipotent Autolog | Limited availability |

Transfection of cells with modified synthetic mRNA




Application of cardiomyocytes generated from iPSCs into the myocardium

How can we deliver these cardiomyocytes into the myocardium?



<http://www.nature.com/nm/journal/v19/n4/images/nm.3147-F1.jpg>

Application of cardiomyocytes generated from iPSCs into the myocardium



XenoLight DiR fluorescent dye

www.nature.com/scientificreports


**SCIENTIFIC
REPORTS**
nature research

Check for updates

OPEN **Hydrojet-based delivery of footprint-free iPSC-derived cardiomyocytes into porcine myocardium**

Marbod Weber¹, Andreas Fech², Luise Jäger², Heidrun Steinle¹, Louisa Bühler², Regine Mariette Perl³, Petros Martirosian³, Roman Mehling⁴, Dominik Sonanini⁴, Wilhelm K. Aicher⁵, Konstantin Nikolaou³, Christian Schlensak¹, Markus D. Enderle², Hans Peter Wendel¹, Walter Linzenbold² & Meltem Avci-Adali^{1,2,5}

mRNA releasing hydrogels




Article

Incorporation of Synthetic mRNA in Injectable Chitosan-Alginate Hybrid Hydrogels for Local and Sustained Expression of Exogenous Proteins in Cells



Heidrun Steinle, Tudor-Mihai Ionescu, Selina Schenk, Sonia Golombek, Silju-John Kunnakattu, Melek Tutku Özbek, Christian Schlensak, Hans Peter Wendel and Meltem Avci-Adali *

Department of Thoracic and Cardiovascular Surgery, University Hospital Tuebingen, Calwerstraße 7/1, 72076 Tuebingen, Germany; heidi.steinle@googlemail.com (H.S.); tudor_mihai.ionescu@yahoo.de (T.-M.I.); schenkse@hs-albsig.de (S.S.); sonia.golombek@klinikum.uni-tuebingen.de (S.G.); silju_j1984@yahoo.de (S.-J.K.); mtutkuozbek@gmail.com (M.T.O.); Christian.Schlensak@med.uni-tuebingen.de (C.S.); hans-peter.wendel@med.uni-tuebingen.de (H.P.W.)


* Correspondence: meltem.avci-adali@uni-tuebingen.de



Modification of endothelial progenitor cells (EPCs) using synthetic mRNA





Application



Anwendung von synthetischer mRNA zur Modifikation von Zellen

Tube formation assay



Modification of endothelial progenitor cells (EPCs) using synthetic mRNA

Molecular Therapy Nucleic Acids

Volume 13, 7 December 2018, Pages 387-398

[open access](#)





Original Article



Improving the Angiogenic Potential of EPCs via Engineering with Synthetic Modified mRNAs

Heidrun Steinle¹, Sonia Golombek¹, Andreas Behring¹, Christian Schlenzak¹, Hans Peter Wendel¹, Meltem Avci-Adali¹

Chorion-Allantois-Membran (CAM) assay



Modification of endothelial progenitor cells (EPCs) using synthetic mRNA



→ ANG-1 mRNA transfected EPCs showed significantly enhanced angiogenic potential

Footprint-free generation of autologous rejuvenated skeletal myocytes for sphincter muscle repair

Dept. of Urology

DFG Deutsche
Forschungsgemeinschaft

Fused myotubes

